CanBas Co., Ltd. (4575) AI Stock Analysis

• Market Cap: ¥17.37B
• Dividend Yield: N/A
• Average Volume (3M): 268.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: N/A
• EPS Growth: 14.03%
• Country: JP
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,713,655
• 10 Day Avg. Volume: 208,910
• 30 Day Avg. Volume: 268,476
• PEG Ratio: 1.96
• Price to Book (P/B): 7.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -29.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ¥961.00 ▲(22.11% Upside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is primarily held back by weak financial performance—persistent losses, minimal revenue, and ongoing cash burn—despite balance-sheet de-risking from zero debt and higher equity. Technical indicators are moderately supportive with price above key medium-term averages and positive momentum, while valuation remains constrained by a negative P/E and no dividend yield.

Positive Factors

Balance sheet strength: zero debt, rising equity

Zero reported debt from 2023–2025 and a material increase in equity materially reduce solvency risk for a pre-commercial biotech. This stronger capital structure lengthens runway, improves partner confidence, and lowers near-term refinancing pressure for clinical programs.

Partnering/licensing-based revenue model

A business model focused on partnering, licensing, and milestone/royalty payments is durable for small biotechs: it enables capital-efficient development, leverages partners' commercialization resources, and can generate non-dilutive cash if clinical progress attracts deals.

Improving cash-burn trend in latest year

Year-over-year reduction in operating/free cash outflow and a slightly narrower net loss indicate improving operational efficiency or better cost control. If sustained, this trend lowers near-term funding needs and increases the odds of reaching a partnership milestone before major dilution.

Negative Factors

Persistent operating and net losses

The company remains a pre-commercial biotech with recurring operating and net losses and effectively zero recent revenue. This leaves earnings quality and long-term profitability dependent on successful clinical outcomes or external licensing, creating structural profitability risk.

Ongoing negative cash flow and financing reliance

Consistent negative operating and free cash flow necessitates recurring external funding to sustain R&D and trials. Continued reliance on financing elevates dilution and execution risk, and weak cash generation reduces strategic flexibility for advancing multiple programs concurrently.

Shareholder value erosion; negative ROE

A roughly -39% ROE in 2025 signals ongoing erosion of shareholders' capital. Persistent negative returns make equity financing costly and indicate current investments have not translated to value creation, complicating long-term capital allocation and investor confidence.

CanBas Co., Ltd. Business Overview & Revenue Model

Company Description

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

How the Company Makes Money

CanBas Co., Ltd. generates revenue primarily through the successful development and commercialization of its pharmaceutical products and technologies. The company invests in research and development to create proprietary drugs, which it can then license to larger pharmaceutical companies or bring to market itself. Revenue streams include milestone payments from licensing agreements, royalties from drug sales, and potentially direct sales of its pharmaceutical products. Additionally, strategic partnerships and collaborations with other biotech or pharmaceutical firms play a crucial role in its revenue model, providing both financial support and access to broader markets for its developed therapies.

CanBas Co., Ltd. Financial Statement Overview

Summary

Income statement fundamentals are weak with recurring operating/net losses and revenue effectively near zero in recent years, consistent with a pre-commercial biotech. Cash flow is persistently negative (ongoing burn), though the latest year shows some improvement. The main offset is a strengthened balance sheet with zero debt reported (2023–2025) and materially higher equity, reducing near-term leverage risk.

Income Statement

The income statement shows persistent operating losses and net losses across all reported years, with gross profit also negative—consistent with a pre-commercial biotech still funding R&D rather than generating product revenue. Revenue has fallen to effectively zero in recent years (vs. ~¥109–110m in 2020–2021), and profitability has not yet stabilized, keeping overall earnings quality and visibility weak. A modest positive is that the latest annual net loss (2025) is slightly narrower than 2023–2024, but the business remains firmly loss-making.

Balance Sheet

The balance sheet looks comparatively healthier: total debt is reported at zero from 2023–2025, and equity has increased materially (from ~¥0.25bn in 2022 to ~¥2.94bn in 2025), indicating improved capitalization and reduced leverage risk versus earlier years when debt-to-equity was high (>1x in 2021–2022 and >3x in 2020). The key weakness is ongoing value erosion from losses, reflected in consistently negative returns on equity (still about -39% in 2025), meaning shareholders’ capital is not yet generating sustainable returns.

Cash Flow

Cash flow remains a major pressure point: operating cash flow and free cash flow are negative every year shown, indicating continuing cash burn to fund operations. There is some improvement in the latest year (2025 operating/free cash flow of about -¥0.77bn vs. about -¥1.28bn in 2024), but the company is still not self-funding and will likely remain dependent on external financing until revenue traction improves.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	108.94M
Gross Profit	-820.00M	-984.00M	-671.00M	-608.00M	-322.00M
EBITDA	-1.16B	53.65M	-1.28B	-848.65M	-522.28M
Net Income	-1.16B	-1.21B	-1.24B	-855.58M	-531.03M
Balance Sheet
Total Assets	3.05B	2.43B	2.09B	790.71M	1.30B
Cash, Cash Equivalents and Short-Term Investments	2.83B	1.89B	1.62B	737.77M	1.15B
Total Debt	0.00	0.00	0.00	367.34M	749.99M
Total Liabilities	107.00M	91.99M	153.85M	540.02M	857.64M
Stockholders Equity	2.94B	2.34B	1.93B	250.69M	437.97M
Cash Flow
Free Cash Flow	-771.45M	-1.28B	-1.40B	-719.81M	-688.57M
Operating Cash Flow	-771.45M	-1.28B	-1.40B	-719.81M	-688.57M
Investing Cash Flow	122.00K	0.00	0.00	182.00K	0.00
Financing Cash Flow	1.75B	1.54B	2.27B	282.75M	728.80M

CanBas Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 787.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Positive. The current price of 787 is below the 20-day moving average (MA) of 870.60, below the 50-day MA of 853.04, and below the 200-day MA of 977.71, indicating a neutral trend. The MACD of -0.72 indicates Positive momentum. The RSI at 53.29 is Neutral, neither overbought nor oversold. The STOCH value of 45.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4575.

CanBas Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4575	51 Neutral	¥17.37B	-13.73	―	―	―	14.03%
4593	50 Neutral	¥59.40B	-18.92	―	―	-82.33%	47.73%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%